Real-world efficacy and safety of cefepime for pediatric community-acquired pneumonia: a propensity score-matched study
Abstract
Objective This study aimed to evaluate the real-world clinical efficacy and safety of cefepime in treating pediatric community-acquired pneumonia (CAP), comparing it with other broad-spectrum antibiotics, including cefoperazone-sulbactam and meropenem, using a propensity score-matched design. Methods A retrospective, propensity score-matched cohort study was conducted in pediatric patients (0–18 years) hospitalized with CAP. Patients treated with cefepime were compared to those treated with cefoperazone-sulbactam or meropenem. Clinical outcomes, microbiological clearance, and adverse events were assessed, and propensity score matching was applied to minimize confounding. Results A total of 788 patients were included, with 720 in the cefepime group and 68 in the comparator group. Both groups showed comparable clinical efficacy, with no significant differences in symptom resolution, laboratory normalization, or radiographic improvement. Microbiological clearance rates were also similar between the groups. The incidence of adverse events was low in both groups, and no statistically significant difference in adverse events was observed between cefepime and the comparator group. Conclusion Our results suggest that cefepime is a clinically effective and well-tolerated alternative to other broad-spectrum antibiotics for pediatric CAP, demonstrating comparable clinical outcomes and safety profiles. These findings support cefepime as a viable empiric therapy option, particularly in…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 788 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.